Brief: Bruno Wohschlegel To Leave Apontis Pharma As CEO End Of August
20/08/2025 15:03
Aug 20 (Reuters) - APONTIS PHARMA AG APPHG.DE: BRUNO WOHSCHLEGEL TO LEAVE APONTIS PHARMA AS CEO END OF AUGUST WOHSCHLEGEL TO SUPPORT APONTIS PHARMA AS ADVISOR UNTIL SEPTEMBER SUCCESSOR FOR APONTIS PHARMA CEO TO BE ANNOUNCED SOON SHARES TRADING TO END AFTER MERGER SQUEEZE-OUT Source text: ID:nEQ9JMmPwa Further company coverage: APPHG.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Apontis Pharma AG
See all newsBrief: Bruno Wohschlegel To Leave Apontis Pharma As CEO End Of August
Brief: APONTIS PHARMA Q1 EBITDA EUR 1.3 Million
Brief: Apontis Pharma Says Zentiva AG Submits Formal Request To Carry Out A Merger
Brief: Zentiva Says Amendeds Offer To Acquire Each Outstanding Share Of Apontis Pharma In Cash By Waiving Condition Of A Minimum Acceptance
Brief: Apontis Pharma: Zentiva To Launch Voluntary Public Purchase Offer At EUR 10.00 Per Share